CTOs on the Move

Beam Therapeutics

www.beamtx.com

 
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.beamtx.com
  • 26 Landsdowne Street 2nd Floor
    Cambridge, MA USA 02139
  • Phone: 857.327.8775

Executives

Name Title Contact Details
Nicholas Meghri
Associate Director, IT Business Partnership Profile
Brian Riley
Senior Vice President of Technical Operations Profile
Brad Dutot
Vice President, Information Technology Profile

Funding

Beam Therapeutics raised $13M on 04/27/2018
Beam Therapeutics raised $74M on 05/14/2018
Beam Therapeutics raised $11M on 03/06/2019
Beam Therapeutics raised $260M on 01/19/2021

Similar Companies

ABL Medical

ABL Medical, LLC

Mary Crowley Medical Research

Mary Crowley Medical Research is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Mccrone Group Inc

Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.